Tuesday - April 29, 2025

LOGIN  |  REGISTER
Compass Therapeutics

InnovAge Announces Participation at the 44th Annual Goldman Sachs Global Healthcare Conference

June 05, 2023 | Last Trade: US$3.11 0.06 1.97

DENVER, June 05, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced that Patrick Blair, president and CEO, and Barbara Gutierrez, CFO will be speaking at the 44th Annual Goldman Sachs Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. (PT) / 12:20 p.m. (ET). The event will be webcast live, and a link for the event will be available online on the investor relations section of the Company’s website.

About InnovAge

InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors. Our mission is to enable seniors to age independently in their own homes for as long as safely possible. Our patient-centered care model is designed to improve the quality of care our participants receive, while reducing over-utilization of high-cost care settings. InnovAge believes its healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of March 31, 2023, InnovAge served approximately 6,310 participants across 17 centers in five states. https://www.innovage.com/.

Investor Contact:
Ryan Kubota
rkubota@myinnovage.com

Media Contact:
Lara Hazenfield
lhazenfield@innovage.com

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page